Welcome to our dedicated page for Rocket Pharmaceu news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceu stock.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company developing investigational genetic therapies for rare and often life-threatening disorders. The RCKT news feed on Stock Titan aggregates company announcements, press releases and third-party coverage related to its AAV and lentiviral gene therapy programs.
Investors following Rocket’s news can track updates on its adeno-associated viral (AAV) cardiovascular portfolio, which includes RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM) and RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM). News items frequently cover clinical trial milestones, such as FDA lifting a clinical hold on the pivotal Phase 2 trial of RP-A501, preliminary Phase 1 data for RP-A601, and IND clearance and Fast Track designation for RP-A701.
The news stream also highlights developments in Rocket’s lentiviral (LV) hematology portfolio, including regulatory progress for KRESLADI (marnetegragene autotemcel; marne-cel) in severe leukocyte adhesion deficiency-I (LAD-I). Articles may discuss FDA acceptance of the resubmitted Biologics License Application (BLA), the setting of a Prescription Drug User Fee Act (PDUFA) target action date, and clinical data showing survival and infection outcomes in treated patients.
Beyond pipeline updates, RCKT news includes financial results, strategic corporate reorganization and pipeline prioritization announcements, leadership and board changes, equity inducement grants and participation in major healthcare investor conferences. By reviewing this page regularly, readers can follow how Rocket’s clinical, regulatory and corporate events may influence sentiment around RCKT stock and gain context on the company’s progress in gene therapy for rare cardiovascular and hematologic diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Rocket Pharmaceuticals, a leader in genetic therapies for rare disorders, announced participation in two key events: the 22nd Annual Needham Virtual Healthcare Conference and Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.
The Needham Conference is scheduled for April 18, 2023, at 8:45 a.m. ET, while the Chardan Summit will take place on April 25, 2023, at 9:00 a.m. ET. Both presentations will be accessible via a webcast on the company’s investor website.
Rocket’s pipeline includes therapies for conditions like Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Danon Disease, demonstrating its commitment to addressing high unmet medical needs.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has expanded its leadership team to bolster its gene therapy initiatives.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has announced CEO Gaurav Shah's participation in the Genetic Medicines Corporate Panel at the Cowen Health Care Conference in Boston, MA, on March 6, 2023, at 10:30 a.m. ET. The conference will feature a live audio webcast accessible via the Investors section on their website. Rocket is focused on developing genetic therapies for rare disorders, including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency, utilizing lentiviral and adeno-associated virus-based technologies.
For more details, visit Rocket's website.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced significant advancements in its gene therapy pipeline for rare disorders, reporting strong clinical results across four programs, including Danon Disease and Fanconi Anemia. The company secured Regenerative Medicine Advanced Therapy (RMAT) designation for RP-A501, with a pivotal trial expected in Q2 2023. Financially, Rocket reported cash reserves of approximately $400M, sufficient to support operations through 2024. Notably, their R&D expenses rose to $165.6M for the year, contributing to a net loss of $221.9M. Additionally, the acquisition of Renovacor led to expanded capabilities in AAV-based therapies.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced that CEO Gaurav Shah, M.D. will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16, at 2:20 p.m. ET. This event will discuss Rocket's innovative pipeline of genetic therapies aimed at rare disorders including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency. A live audio webcast will be available on the company's website, and a replay will follow the event. Rocket focuses on developing advanced genetic therapies to address high unmet medical needs in rare diseases.
FAQ
What is the current stock price of Rocket Pharmaceu (RCKT)?
What is the market cap of Rocket Pharmaceu (RCKT)?
